Drug intelligence / Profile preview

Aliaxin

Development stage
Unknown
Lead developer
IBSA
Modality
Hydrogel Systems → Drug Delivery Systems
Administration
Intradermal, Subcutaneous
01

Overview

Aliaxin is a line of monophasic hyaluronic acid (HA) dermal fillers developed by IBSA Farmaceutici Italia. The product range utilizes cross-linked HA hydrogels produced via a proprietary process that combines different molecular weights of HA to achieve specific viscoelastic properties tailored for various facial regions. The line includes several formulations such as Aliaxin EV (Essential Volume) for deep volume restoration, Aliaxin FL (Lips) for lip contouring, Aliaxin GP (Global Performance) for common facial imperfections, and Aliaxin SR (Shape & Restore) for dermal remodeling. These fillers are designed to provide "Hydrolift Action," which aims to restore facial volume while simultaneously improving skin hydration, elasticity, and tone. They are primarily used in aesthetic medicine for the correction of nasolabial folds, malar volume deficiency, and lip augmentation.

Brand names
AliaxinAliaxin EVAliaxin FLAliaxin SRAliaxin GPAliaxin LVAliaxin SV
Other names
Aliaxin Essential VolumeAliaxin LipsAliaxin Shape & RestoreAliaxin Global PerformanceAliaxin Lips VolumeAliaxin Superior Volumehyaluronic acid dermal fillercross-linked hyaluronic acid

Beyond the preview

Go deeper on Aliaxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aliaxin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call